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Introduction
Prostaglandins (PGs) have numerous cardiovasc ular and inflammatory e ffec ts. 1 Cycloox yge nase (COX) is the first enzyme in the pathw ay in w hich arachidonic acid is conve rted to PGs.
2 ,3 COX ex ists in at least tw o isoforms. One is the constitutiv e e nzyme , COX-1, producing re gulatory prostanoids under physiologic al conditions, 4 w hereas the other, COX-2, is induc ed by mitogens, 5, 6 and p roinflammatory cytokines 7 ,8 during pathologic al states such as inflammation.
The main PGs produc ed in the body are prostacyclin (PGI 2 ), PGE 2 , PGF 2 a , Thrombox ane A 2 (TXA 2 ) and PGD 2 . Each PGs has different charac te rs and functions. Among the PGs, PGE 2 is a potent lipid molecule w ith c omplex proinflammatory and immunoregulatory p rope rties.
9 PGE 2 is considered a major contributor to the production and maintenanc e of immunosuppression after overw he lming injury.
1 0 PGE 2 is believed to modulate biochemic al and immunologic al e ve nts le ading to p arturition. 11 PGE 2 also ex e rts a variety of biologic al ac tivities for the mainte nance of local homeostasis in the body. 1 2 Inte restingly, w e have show n in p re vious studie s that the induc tion of COX-2 e lic ite d by e ndotox in (lipopolysaccharide , LPS) in e ndothelial c ells is inhibite d by PGE 1 and 13,14-dihydro PGE 1 . 1 3 Eluc idation of the effects of PGE 2 on the signalling molec ule such as COX could lead to potential therape utic interve ntions and unde rstanding of the fee dback re gulation of COX in e ndothelial c ells. Here , w e have inve stigated the effects of PGE 2 on the induc tion of COX-2 in human umbilical ve in endothe lial ce lls (HUVEC) treate d w ith inte rleukin-1b (IL-1b ) (1 ng /ml).
Material and methods

Cell culture
Human umbilic al ve in e ndothelial ce lls (HUVEC) w ere obtaine d from babies born to normal pregnant w ome n as pre viously de sc ribe d 1 4 and c ulture d in 96-w ell plates w ith Human Endothelial-SFM Basal Grow th Medium (Gibco) containing 10% fetal calf se rum (Gibco), 100 units /ml pe nicillin G sodium and 100 m g /ml streptomycin. Ce lls w ere inc ubate d at 37°C in a humidified inc ubator and grow n to confluenc e before use. 
Measurement of COX activity
Immunoblot (Western blot) analysis
HUVEC w hich w e re untre ate d, treated w ith IL-1b (1 ng /ml), IL-1b (1 ng /ml) plus PGE 2 (0.03, 0.3 and 3 m M) or PGE 2 (3 m M) alone w ere cultured in six -w e ll culture plates (37°C; for 24 h). After 24 h inc ubation, ce lls w ere ex trac te d and analyse d by immunoblotting using spe cific antibodies for COX-1 and COX-2 prote in (a gene rous gift from Dr Gary O'Ne ill, Merck Frosst, Canada) as pre viously described. 15 The othe r ex periment w as performed to study the signalling mole cule in the e ffec ts of PGE 2 on COX ex pre ssion by using forskolin (cAMP activator). HUVEC w ere treated w ith no addition, IL-1b (1 ng / ml), IL-1b (1 ng /ml) plus PGE 2 (3 m M), IL-1b (1 ng /ml) plus PGE 2 (3 m M) w ith forskolin (10, 50 and 100 m M), IL-1b (1 ng /ml) plus forskolin (100 m M), PGE 2 (3 m M) plus forskolin (100 m M), forskolin (100 m M) alone or PGE 2 (3 m M) alone for 24 h, after w hich time, the me dium w as removed and re place d w ith fre sh me dium c ontaining ex oge nous arachidonic ac id (10 m M for 10 min). The me dium w as then removed to me asure COX activity by 6-ke to-PGF 1 a production. The re mained c ells w ere ex tracted and analyse d by immunoblotting using spe cific antibodies for COX-1 and COX-2 prote in.
Measurement of cell viability
Ce ll respiration, an indicator of c ell viability, w as asse sse d by the mitochondrial-depe ndent reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan. 16 At the end of each ex pe riment, ce lls in 96-w e ll plate s w ere inc ubate d (37°C; 1 h) w ith MTT (0.2 mg /ml) dissolved in culture me dium, after w hich time , the me dium w as remove d by aspiration and ce lls w ere solubilized in DMSO (200 m l e ach w e ll). The ex te nt of reduction of MTT to formazan w ithin ce lls w as quantitate d by the measureme nt of optical density at 650 nm (OD 65 0 ) using a mic roplate reade r (BIORAD, USA).
Statistical analysis
The re sults are show n as mean standard e rror of the me an (SEM) of triplicate de te rminations (w e lls) from at least four separate ex perimental days (n =12). Student's paire d or unpaired t-te sts, as ap propriate, w ere use d for the de te rmination of significanc e of differences betw ee n me ans and a P value of less than 0.05 w as taken as statistically significant. Materials DMSO, phosphate buffe red saline (PBS; pH 7.4), Trizma base , EDTA, triton X-100, phenylme thylsulphonyl fluoride (PMSF), pe pstatin A, le upeptin, glycerol, bromphenol blue, 2-mercaptoethanol, sodium dodec yl sulphate (SDS), forskolin, anti-rabbit IgG antibody, goat IgG, premix e d BCIP/NBT solution, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe nyltetrazolium bromide (MTT), pe nicillin G sodium and stre ptomycin w ere supplied by Sigma Che mical Comp any (St Louis, MO, USA). PGs (6-keto-PGF 1 a , PGE 2 , PGF 2 a and TXB 2 ) and the ir respective ac etylcholineste rase trac er and rabbit antiserum, pre-coated mouse anti-rabbit IgG microtitre plates (96-w ell) and Ellman's reage nt w ere purchased from Cayman (Sapphire Biosc ie nc e, Australia). Human Endothelial-SFM Basal Grow th Me dium and fetal calf serum w as obtained from GibThai (Thailand). Rec ombinant human IL-1b , w ere purchased from Ge nzyme (USA). Pure nitroc ellulose me mbrane (0.45 mic ron) and filte r pape r w ere purchased from BIO-RAD (USA).
Results
The effect of PGE 2 on COX activity as measured by the production of 6-keto-PGF 1 a , PGE 2 , PGF 2 a and TXB 2 in HUVEC treated with IL-1b (1 ng/ml) Untreate d HUVEC in the presenc e of arachidonic acid (10 m M for 10 min) re le ase low er amounts of 6-ke to-PGF 1 a (3.36 ± 0.1 ng /ml), PGE 2 (0.4 ± 0.04 ng /ml), PGF 2 a (0.78 ± 0.01 ng /ml) and TXB 2 (0.04 ± 0.01 ng /ml). In IL-1b (0.01, 0.1 and 1 ng /ml) tre ate d HUVEC; the produc tion of 6-keto-PGF 1 a , PGE 2 and PGF 2 a w as increase d but not TXB 2 (Fig. 1) . The production of 6-keto-PGF 1 a in HUVEC treate d w ith IL-1b (0.01, 0.1 and 1 ng /ml) w as increase d significantly in a dose-depende nt manne r (Fig. 1A) . This incre ase w as signific antly at 0.01 ng /ml of IL-1b . The others, PGE 2 but not PGF 2 a , w as only increase d significantly in HUVEC treated w ith IL-1b 1 ng /ml (Fig. 1B) . In HUVEC tre ated w ith PGE 2 (3 m M) alone, COX me tabolite s did not change significantly w hen compared to untreated HUVEC (Fig. 2) . Inte re stingly, the inc reased 6-ke to-PGF 1 a and PGE 2 in IL-1b (1 ng / ml) treated HUVEC w as signific antly inhibite d by PGE 2 (0.03, 0.3 or 3 m M) in a dose-depe nde nt manner (Fig. 2) . This inhibition w as significant at 0.03 m M of PGE 2 .
IL-1b alone , PGE 2 alone and IL-1b plus PGE 2 did not affec t on cells viability (97 ± 2, 98 ± 1 and 98 ± 1%, respective ly) w hen compare to the control untreate d ce lls over a 24-h incubation pe riod.
The stability of PGE 2 (3 m M) in c ulture d me dium upto 24 h w as also te ste d and has not change d significantly be tw ee n 3 (2.97 ± 0.2), 6 ( 2.98 ± 0.1), 12 (2.95 ± 0.2) and 24 (2.97 ± 0.2) hours inc ubation of PGE 2 .
The effect of PGE 2 on COX isoform expressed in HUVEC treated with IL-1b
Untre ated HUVEC contained no COX-2 prote in (Fig.  3) . COX-2 prote in w as ex pre sse d in HUVEC treated w ith IL-1b (1 ng /ml; Fig. 3 ) for 24 h. Intere stingly, this induc tion of COX-2 in HUVEC tre ated by IL-1b (1 ng / ml) w as inhibited by PGE 2 (0.03, 0.3 or 3 m M) in a dose-depende nt manne r (Fig. 3) . The amount of COX-1 prote in ex pre sse d in HUVEC treated w ith IL-1b (1 ng /ml), IL-1b (1 ng /ml) plus PGE 2 (3 m M) or PGE 2 (3 m M) alone w as not changed w hen c ompared to untreate d HUVEC (Fig. 4) .
The effect of forskolin on 6-keto-PGF 1 a production in HUVEC treated with IL-1b plus PGE 2 The COX ac tivity (as measured by 6-keto-PGF 1 a production) in HUVEC tre ate d w ith forskolin (100 m M) plus PGE 2 (3 m M) or forskolin (100 m M) alone w as not changed in comparison w ith untre ate d HUVEC ( Fig. 5; w hite bar) . Interestingly, the inhibition of increased COX activity in IL-1b (1 ng / ml) treated HUVEC by PGE 2 w as re ve rsed in a dosedepende nt manne r w he n ce lls w e re coinc ubate d w ith forskolin (10, 50 or 100 m M; Fig. 5 ; black and hatch bar). Moreover, the incre ased COX activity in IL-1b (1 ng /ml) tre ated HUVEC w as syne rgise d w hen ce lls w e re coincubated w ith forskolin (100 m M; Fig.  5 ; black bar). prote in (Fig. 6 ; lane s 3 and 8, respe ctive ly). Similarly in COX ac tivity, the inhibition of COX-2 induced in IL-1b (1 ng /ml) tre ate d HUVEC by PGE 2 w as also re verse d w hen ce lls w ere c oinc ubate d w ith forskolin (100 m M; Fig. 6; lanes 4 to 6) . How e ve r, unlike COX activity, the amounts of COX-2 prote in induc ed in IL-1b (1 ng /ml) tre ate d HUVEC w as slightly inc reased w he n cells w ere coinc ubate d w ith forskolin (100 m M; Fig. 6; lane 7) . The amount of COX-1 prote in ex pressed in HUVEC tre ate d w ith foskolin (100 m M) alone, IL-1b (1 ng /ml) plus PGE 2 (3 m M), IL-1b (1 ng /ml) plus PGE 2 (3 m M) w ith forskolin (100 m M), IL-1b (1 ng /ml) p lus forskolin (100 m M) or PGE 2 (3 m M) plus forskolin (100 m M) w as not changed w hen compare d to untre ated HUVEC (Fig. 7) .
PGE 2 in hibit COX-2 indu ctio n th ro u g h cAMP
Mediators of
Discussion
He re, w e show ed that the induction of COX-2 e licite d by IL-1b in HUVEC c an be inhibited by PGE 2 in a dosedepende nt manne r. Moreover, PGE 2 had no affe ct on either COX-1 protein or ac tivity. Inte restingly, forskolin (cAMP activator) can re ve rse this inhibition of PGE 2 on COX-2 protein and activity in IL-1b tre ate d HUVEC. The results sugge ste d that (i) PGE 2 is a ne gative fe edback regulator through c AMP in the induc tion of COX-2 elic ited by IL-1b in e ndothelial ce lls and (ii) the use s of PGE 2 in the c ondition in w hich COX-2 has be en involved may be therapeutic.
PGs induc e a w ide range of biological actions that are mediate d by spe cific membrane-bound rec eptors. Among the PGs, PGE 2 is considered to ex ert a varie ty of biologic al activities such as the maintenanc e of loc al homeostasis in the body, 12 it is a major contributor to the production and maintenanc e of immunosuppression afte r ove rw helming injury 10 and an imp ortant factor for implantation and dec idualization. 1 7 Therefore , PGE 2 is a lipid molec ule w ith complex inflammatory modulation and immunoregulatory prop erties. Our results have be en supported that PGE 2 c an ac t as anti-inflammation and immunosuppression in the induction of COX-2 in endothelial ce lls by IL-1b .
The ex act mechanisms by w hich PGE 2 inhibite d COX-2 induction in e ndothelial c ells ac tivated w ith IL1b are not know n. These may involve binding to spe cific c ell surface rece ptors and influe nc ing sec ond me sse nger syste ms through G-prote ins. Inde ed, the se should be c omplex because the e ffec ts of PGE 2 are ex e rted by a varie ty of PGE re ceptors w hich are different in their signal transduc tion p rope rties. 1 8 There are at least four subtypes of PGE rece ptors. The EP1 and EP3 re ce ptors are couple d to Ca 2 + mobiliz ation and the inhibition of ade nylate cyclase, re spe ctively, and the EP2 and EP4 re cep tors are coupled to the same signal transduc tion pathw ay, stimulation of ade nylate cyclase. 1 Fig. 2A ) more than PGI 2 production (20% inhibition; Fig. 2B ) in IL-1b tre ate d endothe lial ce lls. These may ex plain the COX me tabolite s produc ed in IL-1b treated e ndothelial ce lls that PGI 2 rele ased in highest amounts and the lesser ex te nt of PGE 2 , PGF 2 a and TXA 2 , re spec tively. Thus, elucidation of the fe edback re gulation of each COX metabolite w ill help us to unde rstand the varie ty of COX metabolites produc ed in differe nt ce lls and may lead to pote ntial the rapeutic interventions. In our studie s he re , w e show ed that PGE 2 is a ne gative fe edback regulator of the induc tion of COX-2, but not COX-1, in endothelial ce lls activate d w ith IL-1b . The se suggeste d that PGE serie s may have ne gative fe edback re gulation of COX-2 induction in endothelial c ells, since our pre vious study show e d that PGE 1 and PGE 0 c an inhibit the induction of COX-2 in endothe lial c ells activate d w ith LPS.
13 PGE se rie s have bee n use d in clinical disorders such as peripheral vascular oc clusive dise ase s, 2 1 NSAIDsinduc ed gastric ulcer, 2 2 abortion 23 and impote nc e. 2 4 Thus, w e propose d that uses of PGE 2 in the c ondition in w hich COX-2 has bee n involve d may be therapeutic and the e ffec ts of othe r COX me tabolites such as PGI 2 or PGF 2 a on COX-2 ex pressed in different cells should be e luc idate d.
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